PAMELOR (nortriptyline hydrochloride) by ANI Pharmaceuticals is clinical pharmacology the mechanism of mood elevation by tricyclic antidepressants is at present unknown. Approved for depression. First approved in 1977.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
PAMELOR (nortriptyline hydrochloride) is an oral tricyclic antidepressant approved in 1977 for treatment of depression. It works by interfering with the transport, release, and storage of catecholamines, increasing norepinephrine activity while also inhibiting histamine, serotonin, and acetylcholine. The exact mechanism of mood elevation remains incompletely understood.
This legacy antidepressant faces significant competitive pressure (30/100) and approaching LOE, signaling a small, defensive team focused on maintaining niche prescriber relationships.
CLINICAL PHARMACOLOGY The mechanism of mood elevation by tricyclic antidepressants is at present unknown. Nortriptyline hydrochloride is not a monoamine oxidase inhibitor. It inhibits the activity of such diverse agents as histamine, 5-hydroxytryptamine, and acetylcholine. It increases the pressor…
Working on PAMELOR offers minimal career growth potential given its LOE-approaching status, minimal market spending ($2M Part D), and commodity-like competitive positioning. Roles are primarily defensive and focused on managing a declining legacy asset rather than driving innovation or market expansion.
Worked on PAMELOR at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo